

Dragana Radovanovic<sup>1</sup>, Brahmajee K. Nallamothu<sup>2</sup>, Burkhardt Seifert<sup>3</sup>, Osmund Bertel<sup>4</sup>, Franz Eberli<sup>5</sup>, Philip Urban<sup>6</sup>, Giovanni Pedrazzini<sup>7</sup>, Hans Rickli<sup>8</sup>, Jean-Christophe Stauffer<sup>9</sup>, Stephan Windecker<sup>10</sup>, Paul Erne<sup>11</sup>, AMIS Plus Investigators


<sup>1</sup>AMIS Plus Data Center, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland, <sup>2</sup>University of Michigan, Michigan, USA, <sup>3</sup>Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland, <sup>4</sup>Klinik im Park, Herzgefäßszentrum, Zurich, Switzerland, <sup>5</sup>Stadspital Triemli, Zurich, Switzerland, <sup>6</sup>Hôpital de la Tour, Meyrin, Geneva, Switzerland, <sup>7</sup>Cardio Centro, Lugano, Switzerland, <sup>8</sup>Kantonsspital, St. Gallen, Switzerland, <sup>9</sup>Hôpital Cantonal, Fribourg, Switzerland, <sup>10</sup>Inselspital, Berne, Switzerland, <sup>11</sup>Luzerner Kantonsspital, Lucerne, Switzerland

## Objective

Few representative data exist describing temporal trends in the presentation, treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI)

## Methods

**AMIS Plus (Acute Myocardial Infarction in Switzerland)** is a nationwide, prospective, multicenter study of acute coronary syndrome patients hospitalized in Switzerland. Using the AMIS Plus data, patients admitted between 1997 and 2010 with a definite diagnosis of STEMI (clinical symptoms, ECG and/or elevated troponin levels according to the specific hospital cut-off for MI) were included. Immediate and discharge drugs as well as reperfusion therapies among men and women were analyzed using multivariate logistic regression.



## Population


20,363 STEMI patients from 77 hospitals: 5458 women and 14,905 men.

## Results and Outcome


### Baseline characteristics

	Men (N=14,905)	Women (N=5458)	P value
Age, mean yrs (SD)	62.8 (13.0)	71.4 (12.6)	<0.001
Delay (h:min) median	3:10	4:00	<0.001
IQR	1:41, 8:10	2:02, 10:30	
Resuscitation (prior)	5.2%	6.3%	<0.001
Pain at admission	88.0%	85.0%	<0.001
Dyspnea at admission	24.6%	32.2%	<0.001
Atrial fibrillation	3.9%	5.6%	<0.001
Killip class >2	7.2%	9.6%	<0.001
Diabetes mellitus	17.3%	22.6%	<0.001
Hypertension	50.6%	64.9%	<0.001
Dyslipidemia	54.1%	50.3%	<0.001
Current smokers	46.3%	29.9%	<0.001
Obesity (BMI >30)	18.5%	18.9%	0.59
Charlson Index ≥2	18.2%	24.5%	<0.001



### Early drug therapies



### Discharge medication



### Adjusted\*\* OR for STEMI female patients (reference: male)




\*Primary reperfusion – lysis or primary percutaneous coronary intervention (PCI)  
\*\*Adjusted for age, Killip class >2, risk factors (smoking, dyslipidemia, hypertension, diabetes) and comorbidities (Charlson weighted index ≥2) and admission year


### Independent predictors for in-hospital mortality

	OR	95% CI	P value
Female gender	1.10	0.90-1.35	0.37
Age (per year)	1.07	1.06-1.08	<0.001
Killip class >2	7.46	5.97-9.31	<0.001
Diabetes mellitus	1.16	0.88-1.41	0.36
Hypertension	0.80	0.65-0.98	0.035
Dyslipidemia	0.87	0.72-1.06	0.18
Smoking	1.29	1.03-1.63	0.028
Charlson Index ≥2	1.90	1.54-2.35	<0.001
Admission year	0.98	0.94-1.02	0.30

### Reperfusion therapies



### Complications and in-hospital mortality



reduced by 5% per year in men (OR 0.95; 95%CI 0.94-0.97; P<0.001)  
reduced by 6% per year in women (OR 0.94; 95%CI 0.92-0.97; P<0.001)

## Summary of conclusions

- Substantial changes have occurred in treatment and outcome of STEMI among both men and women in Switzerland over the last 14 years.
- Trends developed for the most part in parallel across the two groups, although ongoing disparities in treatment remain.
- However, disparities in treatment were not associated with worse risk-adjusted in-hospital outcomes which suggests that the gender gap in care may be closing in Switzerland.

There are no conflicts of interest